IIC
JUNO

Integrated Investment Consultants’s Juno Therapeutics, Inc. JUNO Stock Holding History

Integrated Investment Consultants’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-60
Closed -$1.87K – 602
2016
Q2 		$2K Sell
60
-1,080
-95% -$44.8K ﹤0.01% 589
2016
Q1 		$48K Buy
+1,140
New +$39.7K 0.03% 353

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Integrated Investment Consultants's JUNO Position: Q3 2016 in Review

Integrated Investment Consultants sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2016, closing a stake of 60 shares — an estimated $1.87K sold.

Integrated Investment Consultants first reported a position in JUNO in Q1 2016 and held it in 2 quarters. The position peaked at $48K in Q1 2016. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

  • Integrated Investment Consultants reported no remaining Juno Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Integrated Investment Consultants sold 60 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $1.87K.
  • Integrated Investment Consultants first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • Integrated Investment Consultants's Juno Therapeutics, Inc. position peaked at $48K in Q1 2016.
  • 169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on Integrated Investment Consultants's 13F filing for Q3 2016, filed 14 Oct 2016.